Shawn C. Owen, PhD

Languages

  • Chinese
  • English

Academic Information

  • Departments: Internal Medicine - Adjunct Assistant Professor, Medicinal Chemistry - Adjunct Assistant Professor, Pharmaceutics and Pharmaceutical Chemistry - Assistant Professor
  • Divisions: Nephrology

Academic Office Information

  • L.S. Skaggs Pharmacy Institute
    30 S 2000 E, Room: 2952
    Salt Lake City, UT 84112

Academic Bio

My training is in Pharmaceutics and Bioengineering and I am passionate about developing therapeutic and diagnostic platforms to enable precision medicine. I have extensive experience in biotherapeutic drug formulation, protein engineering, and bioconjugation techniques. My previous work includes the synthesis and evaluation of antibody-drug conjugates for breast/ovarian cancer; the study of colloidal drug aggregates and the effects on cancer therapeutics; and extracellular matrices for tumor modeling and drug screening. I synthesized the first diels-alder crosslinked hyaluronic acid hydrogel and demonstrated the ability to spatially control chemical conjugation using photo-caged thiols. My current research focus is on 1) controlling the systemic and cellular pharmacokinetics (PK) of antibody-based therapeutics by creating self-amplifying antibody-drug conjugates, 2) evaluating the pharmaceutic stability of antibody-based therapeutics, and 3) engineering binary/ternary complementation-based diagnostic systems that utilize luminescent reporters for detection of important biomarkers. My lab was the first to publish a detailed report on the physicochemical differences in antibody-drug conjugates that results from distinct preparation procedures. We have synthesized many different antibody-drug conjugates, using a range of bioconjugation techniques and various payloads. My lab developed the first three-part split luciferase for use in novel homogeneous immunoassays. In the next phase of our work, our combined expertise and track record allow us to address the issue of toxicity that hinders immunoconjugates by creating new split-enzyme therapeutic platforms.

Education History

Type School Degree
Postdoctoral Fellowship University of Toronto
Drug Delivery and Tissue Engineering
Postdoctoral Fellow
Doctoral Training University of Utah
Pharmaceutics and Pharmaceutical Chemistry
D.Phil.
Undergraduate University of Utah
Chinese
B.A.
Undergraduate University of Utah
Biochemistry
B.S.

Global Impact

Education History

Type School Degree Country
Postdoctoral Fellowship University of Toronto
Drug Delivery and Tissue Engineering
Postdoctoral Fellow Canada

Selected Publications

Journal Article

  1. Arlotta KJ, Owen SC (2019). Antibody and antibody derivatives as cancer therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 11(5), e1556.
  2. Kim SJ, Hatch ST, Dixon AS, Owen SC (2019). Split-enzyme fragment as a single affinity tag that enables protein expression, purification, and functional assays. Biotechnol Bioeng, 116(7), 1575-1583.
  3. Gandhi AV, Arlotta KJ, Chen HN, Owen SC, Carpenter JF (2018). Biophysical Properties and Heating-Induced Aggregation of Lysine-Conjugated Antibody-Drug Conjugates. J Pharm Sci, 107(7), 1858-1869.

Patent

  1. Dixon, AS, Baumgartner, B, Delgado, J, Owen SC (2017). TARGET-BINDING ACTIVATED SPLIT REPORTER SYSTEMS FOR ANALYTE DETECTION AND RELATED COMPONENTS AND METHODS. U.S. Patent No. PCT/US2017/029680. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Dixon, AS, Baumgartner, B, Delgado, J, Owen SC (2017). TARGET-BINDING ACTIVATED SPLIT REPORTER SYSTEMS FOR ANALYTE DETECTION AND RELATED COMPONENTS AND METHODS. U.S. Patent No. US Patent Appl. No. 15/498,291. Washington, D.C.:U.S. Patent and Trademark Office.
  3. James R. Willcockson, Alvin Kwok, Shawn C. Owen (2017). Breast tissue marker.
  4. Yang D. Li, Michael S.. Yu, Shawn C. Owen, Boi Hoa San (2015). Collagen targeted protein therapeutics.